Key result
Menopause accelerates immune-mediated hypertension risk beyond age-matched men and worsens blood pressure control.
Why the study?
Despite pronounced sex and menopause-related differences in hypertension risk, control, and drug efficacy, sex-specific clinical guidelines and female preclinical models of immune-mediated hypertension remain sparse.
This review highlights sex differences and the impact of menopause on immune-mediated hypertension, noting lower hypertension control rates and distinct side effects from ACE inhibitors and beta-blockers in postmenopausal women.
Answers are grounded in this paper and cite their sources.
May warrant menopause-adjusted hypertension evaluation; extends sex-difference evidence but leaves open prospective confirmation.
Hypertension is an inflammatory disease with the immune system playing a key role in mediating hypertensive outcomes and end-organ damage. The risk of hypertension is greater in men than in women before women enter menopause. After menopause, a woman's risk for developing hypertension increases and accelerates beyond that of age-matched men. Moreover, after menopause, the rate of hypertension control in women is lower than in men. Indeed, cardiovascular drug efficacy in women is different from that in men, with recent studies highlighting serious side effects of angiotensin-converting enzyme inhibitors and β-blockers in postmenopausal women. Despite these sex differences, sex-specific clinical practice guidelines are still sparse, as is the consideration of a woman's hormonal status. In addition, preclinical models of immune-mediated hypertension are still mainly performed in male animals. The goal of this review is to highlight recent advancements in the field of sex differences in immune-mediated hypertension and to identify the major gaps in understanding immune mechanisms that lead to hypertension development in males and females, and as menopause progresses.
No takes yet. Share an insight, caveat, or question.
Brooks et al. (2026) conducted a review in Immune-mediated hypertension. Menopause and sex differences vs. Premenopausal women and age-matched men was evaluated. Menopause accelerates immune-mediated hypertension risk in women beyond age-matched men, reduces blood pressure control rates, and alters cardiovascular drug efficacy and side effects.
Synapse has enriched 10 related papers. Consider them for comparative context: